BUGATTI, SERENA
 Distribuzione geografica
Continente #
NA - Nord America 2.723
AS - Asia 2.118
EU - Europa 1.845
SA - Sud America 334
AF - Africa 35
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.062
Nazione #
US - Stati Uniti d'America 2.652
CN - Cina 1.054
SG - Singapore 501
IE - Irlanda 471
HK - Hong Kong 306
RU - Federazione Russa 295
BR - Brasile 271
DE - Germania 258
FI - Finlandia 239
IT - Italia 164
UA - Ucraina 132
VN - Vietnam 96
SE - Svezia 89
GB - Regno Unito 74
CA - Canada 39
IN - India 28
AE - Emirati Arabi Uniti 21
FR - Francia 20
BD - Bangladesh 18
BE - Belgio 18
AR - Argentina 17
JP - Giappone 17
MX - Messico 16
EC - Ecuador 14
ES - Italia 14
IR - Iran 14
CZ - Repubblica Ceca 13
ZA - Sudafrica 12
TR - Turchia 11
AT - Austria 10
NL - Olanda 10
PL - Polonia 10
CO - Colombia 9
ID - Indonesia 9
LT - Lituania 8
VE - Venezuela 8
MA - Marocco 7
PK - Pakistan 7
CL - Cile 6
IL - Israele 6
EG - Egitto 5
RO - Romania 5
SA - Arabia Saudita 5
TH - Thailandia 5
IQ - Iraq 4
PE - Perù 4
AL - Albania 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
JM - Giamaica 3
KZ - Kazakistan 3
NZ - Nuova Zelanda 3
TT - Trinidad e Tobago 3
AU - Australia 2
AZ - Azerbaigian 2
BG - Bulgaria 2
CU - Cuba 2
EU - Europa 2
GR - Grecia 2
KG - Kirghizistan 2
PH - Filippine 2
PY - Paraguay 2
TN - Tunisia 2
UY - Uruguay 2
UZ - Uzbekistan 2
ZM - Zambia 2
BO - Bolivia 1
CH - Svizzera 1
DZ - Algeria 1
ET - Etiopia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
JO - Giordania 1
KE - Kenya 1
KR - Corea 1
LK - Sri Lanka 1
LV - Lettonia 1
MK - Macedonia 1
NA - Namibia 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PT - Portogallo 1
RE - Reunion 1
SK - Slovacchia (Repubblica Slovacca) 1
UG - Uganda 1
Totale 7.062
Città #
Dublin 466
Chandler 415
Dallas 311
Hong Kong 303
Beijing 238
Singapore 226
Ashburn 202
Jacksonville 195
Nanjing 195
Boardman 122
Helsinki 111
Munich 102
New York 85
Princeton 81
Lawrence 75
Wilmington 75
Los Angeles 73
Nanchang 67
Ann Arbor 64
Shenyang 59
Shanghai 56
Medford 51
Hebei 50
Moscow 48
Changsha 47
Redondo Beach 42
Turku 42
Milan 39
Buffalo 38
Jiaxing 36
Ho Chi Minh City 33
Pavia 29
Hangzhou 25
Hanoi 24
São Paulo 22
Tianjin 21
Brussels 18
Dubai 18
Piscataway 18
The Dalles 18
Woodbridge 18
Seattle 17
Tokyo 16
Montreal 15
Santa Clara 15
London 14
Brooklyn 13
Columbus 13
Denver 13
Rio de Janeiro 12
Tabriz 12
Toronto 12
Fairfield 11
Falkenstein 11
Norwalk 11
Nuremberg 11
Stockholm 11
Chennai 9
Warsaw 9
Belo Horizonte 8
Guangzhou 8
Washington 8
Zhengzhou 8
Berlin 7
Johannesburg 7
Poplar 7
Brno 6
Chicago 6
Elk Grove Village 6
Frankfurt am Main 6
Houston 6
Mexico City 6
Orem 6
Quito 6
San Francisco 6
Verona 6
Amsterdam 5
Atlanta 5
Chongqing 5
Hyderabad 5
Kunming 5
Olomouc 5
Phoenix 5
Porto Alegre 5
Ribeirão Preto 5
Taizhou 5
Turin 5
Bangkok 4
Boston 4
Caxias do Sul 4
Curitiba 4
Da Nang 4
Düsseldorf 4
Guayaquil 4
Imperatriz 4
Jakarta 4
Manchester 4
Menlo Park 4
Newark 4
Palhoça 4
Totale 4.603
Nome #
B cells in rheumatoid arthritis. 122
Assessment of synovitis to predict bone erosions in rheumatoid arthritis 121
B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers 119
Anti-neutrophil cytoplasmic antibodies (ANCA) ( Review ) [Anticorpi anticitoplasma dei neutrofili (ANCA)] 109
Analysis of the apoliporotein(a) size polymorphism in patients with systemic lupus erythematosus 105
In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: Comparison of two cohorts treated according to different treat to target protocols 104
Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus 104
B cells in rheumatoid arthritis. 104
Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis 102
CCL21 expression pattern of human secondary lymphoid organ stroma is conserved in inflammatory lesions with lymphoid neogenesis 101
null 97
Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus. 97
Ultrasonographic and MRI characterisation of the palindromic phase of rheumatoid arthritis 96
Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis 96
B cell autoimmunity and bone damage in rheumatoid arthritis 96
Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable? 94
Autoantibodies to heterogeneous nuclear ribonucleoproteins. 93
Janus kinase inhibitors effectively improve pain across different disease activity states in rheumatoid arthritis 92
Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs' 90
A Multicenter Retrospective Analysis Evaluating Performance of Synovial Biopsy Techniques in Patients With Inflammatory Arthritis: Arthroscopic Versus Ultrasound-Guided Versus Blind Needle Biopsy 87
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. 86
Subclinical remodelling of draining lymph node structure in early and established rheumatoid arthritis assessed by power Doppler ultrasonography 85
Nuovi aspetti patogenetici dell’artrite reumatoide 84
B cell synovitis and clinical phenotypes in rheumatoid arthritis: relationship to disease stages and drug exposure 83
Reactogenicity, safety and disease flares following BNT162b2 mRNA COVID-19 vaccine in patients with chronic immune-inflammatory arthritis treated with biological and targeted synthetic disease-modifying anti-rheumatic drugs 83
Involvement of subchondral bone marrow in rheumatoid arthritis: lymphoid neogenesis and in situ relationship to subchondral bone marrow osteoclast recruitment 80
Long term treatment of rheumatoid arthritis with rituximab. 79
Long term treatment of rheumatoid arthritis with rituximab 79
Personalized Therapeutic Strategies in the Management of Osteoporosis in Patients with Autoantibody-Positive Rheumatoid Arthritis 79
Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis 77
Treatment comparison in rheumatoid arthritis: Head-to-head trials and innovative study designs 76
Polyarthrite rhumatoïde associée à un trait bêta-thalassémique : aspect clinique, sérologique et immunogénétique 76
What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated peptide antibodies? 76
Challenges in the diagnosis of early rheumatoid arthritis in times of COVID-19 76
Subchondral Bone Marrow Inflammatory Involvement in Rheumatoid Arthritis: Lymphoid Neogenesis and In Situ Relationship with Subchondral Bone Marrow Osteoclasts 75
Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy 73
The draining lymph node in rheumatoid arthritis: current concepts and research perspectives 73
B cell synovitis and clinical phenotypes in rheumatoid arthritis: relationship to disease stages and drug exposure 73
No evidence of short-term impact of repeated BNT162b2 vaccination on rheumatoid arthritis homeostasis in drug-free remission 72
What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated peptide antibodies? 72
Synovial tissue heterogeneity and peripheral blood biomarkers 72
Early treatment in early undifferentiated arthritis 72
Adult-onset Still's disease with elderly onset, results from a multicentre study 72
Vitamin D 25OH Deficiency and Mortality in Moderate to Severe COVID-19: A Multi-Center Prospective Observational Study 70
Impact of Anti-Citrullinated Protein Antibodies on Progressive Systemic Bone Mineral Density Loss in Patients With Early Rheumatoid Arthritis After Two Years of Treat-to-Target 70
Seronegative autoimmune diseases: A challenging diagnosis 69
A case of a rheumatoid nodule on the aortic valve in a patient with rheumatoid arthritis in sustained remission with anti-TNFα 68
Power Doppler ultrasonographic assessment of the joint-draining lymph node complex in rheumatoid arthritis: a prospective, proof-of-concept study on treatment with tumor necrosis factor inhibitors. 68
Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group 68
Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs 67
The novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synovium 67
Rheumatology training experience across Europe: Analysis of core competences 67
Established rheumatoid arthritis. The pathogenic aspects. 67
A “Window of Therapeutic Opportunity” for Anti-Cytokine Therapy in Patients With Coronavirus Disease 2019 67
Use of ultrasound-guided small joint biopsy to evaluate the histopathologic response to rheumatoid arthritis therapy: recommendations for application to clinical trials 66
Cytokine profile, ferritin, and multi-visceral involvement characterise macrophage activation syndrome during adult-onset Still's disease 66
The constitutive pattern of CCL21 production is maintained in inflammatory lesions with lymphoid neogenesis 65
Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis 65
Insights Into the Concept of Rheumatoid Arthritis Flare 65
Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: Could it be the first step of the treatment? 62
Clinical Applications of Synovial Biopsy. 62
Synovial and serum B-cell signature of autoantibody-negative rheumatoid arthritis versus autoantibody-positive rheumatoid arthritis and psoriatic arthritis 61
Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases 61
Rheumatoid arthritis treatment: the earlier the better to prevent joint damage 61
Long-term safety of abatacept in patients with rheumatoid arthritis 60
Progressive increase in time to referral and persistently severe clinical presentation over the years in autoantibody-negative patients with rheumatoid arthritis in the setting of an early arthritis clinic 60
Anti-neutrophil cytoplasmic antibodies (ANCA) 59
Rheumatoid arthritis in beta-thalassemic trait: clinical, serologic and immunogenetic profile. 59
Dupilumab-induced enthesoarthritis and refractory atopic dermatitis successfully treated with baricitinib 59
In patients with early peripheral psoriatic arthritis baseline c-reactive protein, pain and ultrasound-detected synovitis predict subsequent treatment with ts/bdmards. A retrospective analysis 59
La linfoneogenesi 58
Differences and similarities in rheumatology specialty training programmes across European countries 58
High serum levels of CXCL13 predict lower response to csDMARDs in both ACPA-positive and ACPA-negative early rheumatoid arthritis 57
Cost-effectiveness of the early arthritis clinic organizational model: the ELECTRA study 57
High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease 56
Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. 55
Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline 55
Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry 55
Tumor necrosis factor-α inhibitor-related autoimmune disorders 54
The Clinical Value of Autoantibodies in Rheumatoid Arthritis. 54
Baseline Serum Concentrations of TRAIL in Early Rheumatoid Arthritis: Relationship with Response to Disease-modifying Antirheumatic Drugs. 53
Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA 53
Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter-Determining Validation Requirements 52
Over-expression of miR-223 in T-lymphocytes of early rheumatoid arthritis patients 51
Timely escalation to second-line therapies after failure of methotrexate in patients with early rheumatoid arthritis does not reduce the risk of becoming difficult-to-treat 49
The access route through the anatomical snuffbox in ultrasound-guided synovial biopsy of the wrist allows for a safe and effective collection of tissue samples in inflammatory arthritis 49
Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis 48
Administrative Databases and Diagnostic Therapeutic and Assistance Paths -PDTA- in the Monitoring Treatment of Rheumatoid Arthritis: The Experience of ATS Pavia 48
Clinical Features of Diabetes Mellitus on Rheumatoid Arthritis: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group 45
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial 45
Prediction of long-term drug-free outcomes in ACPA-positive and ACPA-negative rheumatoid arthritis by combined clinical and ultrasound assessment of residual disease: a 5-year prospective study 44
Histopathology of the synovial tissue: Perspectives for biomarker development in chronic inflammatory arthritides. 44
Seronegative rheumatoid arthritis: one year in review 2023 43
Inflammatory lesions in the bone marrow of rheumatoid arthritis patients: a morphological perspective 43
Comorbidities in the Spondyloarthritis GISEA Cohort: an average treatment effect analysis on patients treated with bDMARDs 42
Seronegative rheumatoid arthritis: Neglected in clinical trials, a giant in clinical practice 41
Transient monoarthritis and psoriatic skin lesions following COVID-19 40
Do we need Early Arthritis Clinics to counteract the excess of mortality in rheumatoid arthritis? 39
Increased COVID-19 mortality in patients with rheumatic diseases: results from the CONTROL-19 study by the Italian Society for Rheumatology 38
Autoantibody-negative rheumatoid arthritis: still a challenge for the rheumatologist 38
Totale 7.004
Categoria #
all - tutte 35.410
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.410


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021199 0 0 0 0 0 31 8 51 16 45 37 11
2021/2022362 4 3 12 14 10 26 15 23 19 8 54 174
2022/20231.352 143 103 11 86 104 126 1 72 529 20 50 107
2023/2024626 46 182 22 30 53 149 23 34 11 12 31 33
2024/20251.775 43 111 24 24 21 110 124 101 468 94 236 419
2025/20261.897 307 273 458 374 461 24 0 0 0 0 0 0
Totale 7.425